-
Je něco špatně v tomto záznamu ?
Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic
R. Kucera, O. Topolcan, L. Pecen, J. Kinkorova, S. Svobodova, J. Windrichova, R. Fuchsova,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- dospělí MeSH
- IGFBP-3 krev MeSH
- insulinu podobný růstový faktor I analýza MeSH
- lidé středního věku MeSH
- lidé MeSH
- lineární modely MeSH
- mladý dospělý MeSH
- pohlavní dimorfismus MeSH
- radioimunoanalýza MeSH
- referenční hodnoty MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stárnutí krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
BACKGROUND: IGF1 is responsible for regulation of growth, metabolism and differentiation of human cells. IGFBP3 is the most abundant of the carrier proteins for IGF1 in the blood. IGF1/IGFBP3 molar ratio is an indicator of IGF1 bioavailability. We decided to create a file of reference ranges of IGF1, IGFBP3 and IGF1/IGFBPP3 ratio for the adult Czech population across the age spectrum. METHODS: We selected a group of 1022 subjects, 467 males and 555 females (ages 20-98 years), from several regions in the Czech Republic. The group consisted of blood donors and patients undergoing regular preventive examinations. Serum levels of IGF1 and IGFBP3 were measured using the following radioimmunoassay kits: IRMA IGF1 (Immunotech, Marseille, France) and IRMA IGFBP3 (Immunotech, Prague, Czech Republic). The IGF1/IGFBP3 ratio was also calculated. The following groups of patients were excluded: patients with diabetes, high blood glucose, high insulin levels, post-surgery patients, polymorbid patients, and subjects with oncological diseases. Subjects were divided into seven age-groups. Changes in the levels of observed analytes in each decade across the age spectrum were evaluated. All statistical analyses were performed by SAS 9.3 (Statistical Analysis Software release 9.3; SAS Institute Inc., Cary, NC, USA). RESULTS: All three parameters IGF1, IGFBP3 and IGF1/IGFBP3 decreased in parallel with decrease in age: p<0.0001, r=-0.64, -0.35 and -0.54, respectively. The dynamics of the decline was different between males and females. Linear regression models with age as independent variable fitted by gender are displayed in Fig. 1. Non-parametric reference interval curves (medians and 2.5th-97.5th percentiles) for IGF1, IGFBP3 and IGF1/IGFBP3 ratio as function of age by gender are displayed in Fig. 2(a,b,c). All medians and 2.5th-97.5th percentiles were plotted by cubic spline. For males, linear regression models were as follows: IGF1=291.34619-2.41211 × age, IGFBP3=2931.62778-6.11659 × age, IGF1/IGFBP3=0.02897-0.00021213 × age. For females, we plotted the following: IGF1=241.67406-1.98466 × age, IGFBP3=3688.60561-16.39560 × age, IGF1/IGFBP3=0.02029-0.00013233 × age. IGF1 was statistically significantly higher in males with p<0.0001 (Wilcoxon test) but decreased faster (p=0.0121). IGFBP3 was statistically significantly higher in females with p=0.0004 (Wilcoxon test) but decreased faster (p<0.0001). IGF1/IGFBP3 was statistically significantly higher in males with p<0.0001 (Wilcoxon test) but decreased faster (p<0.0001). CONCLUSION: Authors recommend using of a linear regression model based reference ranges for IGF1, IGFBP3 and IGF1/IGFBP3 ratio and using different reference ranges for genders.
Laboratory of Immunoanalysis Faculty Hospital Pilsen Czech Republic
Medical Faculty Pilsen Charles University Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020947
- 003
- CZ-PrNML
- 005
- 20200720082118.0
- 007
- ta
- 008
- 160722s2015 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cca.2015.02.036 $2 doi
- 024 7_
- $a 10.1016/j.cca.2015.02.036 $2 doi
- 035 __
- $a (PubMed)25744488
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Kucera, Radek $u Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic. Electronic address: kucerar@fnplzen.cz.
- 245 10
- $a Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic / $c R. Kucera, O. Topolcan, L. Pecen, J. Kinkorova, S. Svobodova, J. Windrichova, R. Fuchsova,
- 520 9_
- $a BACKGROUND: IGF1 is responsible for regulation of growth, metabolism and differentiation of human cells. IGFBP3 is the most abundant of the carrier proteins for IGF1 in the blood. IGF1/IGFBP3 molar ratio is an indicator of IGF1 bioavailability. We decided to create a file of reference ranges of IGF1, IGFBP3 and IGF1/IGFBPP3 ratio for the adult Czech population across the age spectrum. METHODS: We selected a group of 1022 subjects, 467 males and 555 females (ages 20-98 years), from several regions in the Czech Republic. The group consisted of blood donors and patients undergoing regular preventive examinations. Serum levels of IGF1 and IGFBP3 were measured using the following radioimmunoassay kits: IRMA IGF1 (Immunotech, Marseille, France) and IRMA IGFBP3 (Immunotech, Prague, Czech Republic). The IGF1/IGFBP3 ratio was also calculated. The following groups of patients were excluded: patients with diabetes, high blood glucose, high insulin levels, post-surgery patients, polymorbid patients, and subjects with oncological diseases. Subjects were divided into seven age-groups. Changes in the levels of observed analytes in each decade across the age spectrum were evaluated. All statistical analyses were performed by SAS 9.3 (Statistical Analysis Software release 9.3; SAS Institute Inc., Cary, NC, USA). RESULTS: All three parameters IGF1, IGFBP3 and IGF1/IGFBP3 decreased in parallel with decrease in age: p<0.0001, r=-0.64, -0.35 and -0.54, respectively. The dynamics of the decline was different between males and females. Linear regression models with age as independent variable fitted by gender are displayed in Fig. 1. Non-parametric reference interval curves (medians and 2.5th-97.5th percentiles) for IGF1, IGFBP3 and IGF1/IGFBP3 ratio as function of age by gender are displayed in Fig. 2(a,b,c). All medians and 2.5th-97.5th percentiles were plotted by cubic spline. For males, linear regression models were as follows: IGF1=291.34619-2.41211 × age, IGFBP3=2931.62778-6.11659 × age, IGF1/IGFBP3=0.02897-0.00021213 × age. For females, we plotted the following: IGF1=241.67406-1.98466 × age, IGFBP3=3688.60561-16.39560 × age, IGF1/IGFBP3=0.02029-0.00013233 × age. IGF1 was statistically significantly higher in males with p<0.0001 (Wilcoxon test) but decreased faster (p=0.0121). IGFBP3 was statistically significantly higher in females with p=0.0004 (Wilcoxon test) but decreased faster (p<0.0001). IGF1/IGFBP3 was statistically significantly higher in males with p<0.0001 (Wilcoxon test) but decreased faster (p<0.0001). CONCLUSION: Authors recommend using of a linear regression model based reference ranges for IGF1, IGFBP3 and IGF1/IGFBP3 ratio and using different reference ranges for genders.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a stárnutí $x krev $7 D000375
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a IGFBP-3 $x krev $7 D018972
- 650 _2
- $a insulinu podobný růstový faktor I $x analýza $7 D007334
- 650 _2
- $a lineární modely $7 D016014
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a radioimunoanalýza $7 D011863
- 650 _2
- $a referenční hodnoty $7 D012016
- 650 _2
- $a pohlavní dimorfismus $7 D012727
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Topolcan, Ondrej $u Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic.
- 700 1_
- $a Pecen, Ladislav $u Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic.
- 700 1_
- $a Kinkorová, Judita, $d 1960- $u Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic. $7 xx0001268
- 700 1_
- $a Svobodova, Sarka $u Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic.
- 700 1_
- $a Windrichová, Jindra $u Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic. $7 xx0209887
- 700 1_
- $a Fuchsova, Radka $u Laboratory of Immunoanalysis, Faculty Hospital Pilsen, Czech Republic; Medical Faculty Pilsen, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00009464 $t Clinica chimica acta; international journal of clinical chemistry $x 1873-3492 $g Roč. 444, č. - (2015), s. 271-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25744488 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20200720082118 $b ABA008
- 999 __
- $a ok $b bmc $g 1155617 $s 945475
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 444 $c - $d 271-7 $e 20150302 $i 1873-3492 $m Clinica chimica acta $n Clin Chim Acta $x MED00009464
- LZP __
- $a Pubmed-20160722